169 related articles for article (PubMed ID: 25333665)
1. Successful treatment of aplastic anaemia associated with HIV infection with eltrombopag: implications for a possible immunomodulatory role.
Bart-Smith EE; Kordasti S; Kulasekararaj AG; Richardson D; Mufti GJ; Marsh JC
AIDS; 2014 Nov; 28(18):2786-8. PubMed ID: 25333665
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
Hwang YY; Gill H; Chan TSY; Leung GMK; Cheung CYM; Kwong YL
Hematology; 2018 Aug; 23(7):399-404. PubMed ID: 29303047
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia.
Cheng H; Wang X; Zhou D; Cao J; Larochelle A; Xu KL
Ann Hematol; 2019 Aug; 98(8):2009-2011. PubMed ID: 30891613
[No Abstract] [Full Text] [Related]
4. An Eltrombopag Red (Plasma) Alert.
Al-Samkari H; Goodarzi K
Acta Haematol; 2021; 144(2):227-228. PubMed ID: 32702690
[TBL] [Abstract][Full Text] [Related]
5. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
Assi R; Garcia-Manero G; Ravandi F; Borthakur G; Daver NG; Jabbour E; Burger J; Estrov Z; Dinardo CD; Alvarado Y; Hendrickson S; Ferrajoli A; Wierda W; Cortes J; Kantarjian H; Kadia TM
Cancer; 2018 Nov; 124(21):4192-4201. PubMed ID: 30307606
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag: a review of its use in patients with severe aplastic anaemia.
McCormack PL
Drugs; 2015 Apr; 75(5):525-31. PubMed ID: 25700916
[TBL] [Abstract][Full Text] [Related]
7. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
Yamazaki H; Ohta K; Iida H; Imada K; Obara N; Tokumine Y; Tomiyama Y; Usuki K; Imajo K; Miyamura K; Sasaki O; Fanghong Z; Hattori T; Tajima T; Matsuda A; Nakao S
Int J Hematol; 2019 Aug; 110(2):187-196. PubMed ID: 31183813
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia.
Quintino de Oliveira B; Catto LFB; Santana BAA; Tellechea MF; Scheucher PS; Scheinberg P; Calado RT
Br J Haematol; 2021 Apr; 193(2):410-414. PubMed ID: 33216370
[TBL] [Abstract][Full Text] [Related]
9. Iron mobilization in a real life cohort of aplastic anemia patients treated with eltrombopag.
Fattizzo B; Cavallaro F; Milesi G; Barcellini W
Am J Hematol; 2019 Sep; 94(9):E237-E239. PubMed ID: 31172568
[No Abstract] [Full Text] [Related]
10. Are eltrombopag plasma and skin hyperpigmentation related? The eyes have it.
Rodgers GM; Kurtti AL; Gilreath JA
Am J Hematol; 2019 Mar; 94(3):394-395. PubMed ID: 30033660
[No Abstract] [Full Text] [Related]
11. Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
Olnes MJ; Scheinberg P; Calvo KR; Desmond R; Tang Y; Dumitriu B; Parikh AR; Soto S; Biancotto A; Feng X; Lozier J; Wu CO; Young NS; Dunbar CE
N Engl J Med; 2012 Jul; 367(1):11-9. PubMed ID: 22762314
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.
Hong Y; Li X; Wan B; Li N; Chen Y
Clin Drug Investig; 2019 Feb; 39(2):141-156. PubMed ID: 30406906
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag as initial monotherapy for severe aplastic anemia-a case report.
Rodgers GM; Gilreath JA
Ann Hematol; 2018 Aug; 97(8):1517-1518. PubMed ID: 29560523
[No Abstract] [Full Text] [Related]
14. [Recent issues and prospects of the treatment of aplastic anemia].
Nakao S
Rinsho Ketsueki; 2014 Jan; 55(1):5-11. PubMed ID: 24492031
[No Abstract] [Full Text] [Related]
15. Eltrombopag in aplastic anemia.
Desmond R; Townsley DM; Dunbar C; Young NS
Semin Hematol; 2015 Jan; 52(1):31-7. PubMed ID: 25578417
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety analysis of eltrombopag and recombinant human thrombopoietin combined with immunosuppressive therapy for severe aplastic anemia].
Yuan FF; Zhang QL; Zhang LN; Xiong YY; Li MJ; Zhou H; Wei XD; Liu XJ; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):1021-1024. PubMed ID: 35045674
[No Abstract] [Full Text] [Related]
17. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.
Fattizzo B; Kulasekararaj AG; Hill A; Benson-Quarm N; Griffin M; Munir T; Arnold L; Riley K; Ireland R; De Lavallade H; Potter V; Consonni D; Hillmen P; Mufti GJ; Barcellini W; Marsh JCW
Haematologica; 2019 Nov; 104(11):e494-e496. PubMed ID: 30890599
[No Abstract] [Full Text] [Related]
18. Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?
Huan Ng C; Jang-Milligan F; Schultz KR
Pediatr Hematol Oncol; 2021 Aug; 38(5):417-419. PubMed ID: 34157932
[No Abstract] [Full Text] [Related]
19. Activity of eltrombopag in severe aplastic anemia.
Scheinberg P
Blood Adv; 2018 Nov; 2(21):3054-3062. PubMed ID: 30425070
[TBL] [Abstract][Full Text] [Related]
20. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.
Lengline E; Drenou B; Peterlin P; Tournilhac O; Abraham J; Berceanu A; Dupriez B; Guillerm G; Raffoux E; de Fontbrune FS; Ades L; Balsat M; Chaoui D; Coppo P; Corm S; Leblanc T; Maillard N; Terriou L; Socié G; de Latour RP
Haematologica; 2018 Feb; 103(2):212-220. PubMed ID: 29170252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
